The BCLI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BCLI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BCLI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BCLI Detailed Price Forecast - CNN Money||View BCLI Detailed Summary - Google Finance|
|View BCLI Detailed Summary - Yahoo! Finance||View BCLI Stock Research & Analysis - Zacks.com|
|View BCLI Trends & Analysis - Trade-Ideas||View BCLI Major Holders - Barrons|
|View BCLI Call Transcripts - NASDAQ||View BCLI Breaking News & Analysis - Seeking Alpha|
|View BCLI Annual Report - CompanySpotlight.com||View BCLI OTC Short Report - OTCShortReport.com|
|View BCLI Fundamentals - TradeKing||View BCLI SEC Filings - Bar Chart|
|View Historical Prices for BCLI - The WSJ||View Performance/Total Return for BCLI - Morningstar|
|View the Analyst Estimates for BCLI - MarketWatch||View the Earnings History for BCLI - CNBC|
|View the BCLI Earnings - StockMarketWatch||View BCLI Buy or Sell Recommendations - MacroAxis|
|View the BCLI Bullish Patterns - American Bulls||View BCLI Short Pain Metrics - ShortPainBot.com|
|View BCLI Stock Mentions - StockTwits||View BCLI Stock Mentions - PennyStockTweets|
|View BCLI Stock Mentions - Twitter||View BCLI Investment Forum News - Investor Hub|
|View BCLI Stock Mentions - Yahoo! Message Board||View BCLI Stock Mentions - Seeking Alpha|
|View Insider Transactions for BCLI - SECform4.com||View Insider Transactions for BCLI - Insider Cow|
|View BCLI Major Holdings Summary - CNBC||View Insider Disclosure for BCLI - OTC Markets|
|View Insider Transactions for BCLI - Yahoo! Finance||View Institutional Holdings for BCLI - NASDAQ|
|View BCLI Stock Insight & Charts - FinViz.com||View BCLI Investment Charts - StockCharts.com|
|View BCLI Stock Overview & Charts - BarChart||View BCLI User Generated Charts - Trading View|
BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
Posted on Thursday January 10, 2019
NEW YORK and IRVINE, Calif., Jan. 11, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis…
Posted on Monday January 07, 2019
On December 17, 2018, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for testing NurOwn® in patients with progressive multiple sclerosis (MS). The company also announced that it has contracted with the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute to expand production of NurOwn to support both the Phase 2 trial in MS as well as support ongoing production for the ongoing Phase 3 trial in amyotrophic lateral sclerosis (ALS).
BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
Posted on Thursday January 03, 2019
NEW YORK, Jan. 03, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today.
BrainStorm Issues 2018 Letter to Shareholders
Posted on Thursday December 27, 2018
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. This past year was an extraordinary success for BrainStorm Cell Therapeutics from a research and development, clinical, financial and corporate perspective.